Move over, amyloid, reactive astrocytes and activated microglia may be the main drivers of the Alzheimer’s disease pathological cascade. In the November 6 Nature Neuroscience, scientists led by Pedro ...

Hypertension heightens the risk of Alzheimer’s disease, but exactly how is not understood. In a bioRxiv preprint posted September 19, scientists led by Costantino Iadecola at Weill Cornell Medical ...

This knock-in (KI) mouse model was generated by introducing a D427V point mutation into exon 10 of the mouse Gba1 (glucosidase, beta, acid 1) gene, which corresponds to the human D409V mutation (The ...

The gene PSEN2 encodes presenilin-2, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. Missense mutations in PSEN2 are a rare cause of early onset Alzheimer's disease.

Building 114, Suite 2011 16th Street Charlestown, MA02129 United States Visit Website Contact: Bradley T. Human, M.D., Ph.D. Phone: (617) 726-3987 E-mail: [email protected] Brain Banks Home ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected].

In September 2016, the Cocoa Supplement and Multivitamin Outcomes Study of Cognition (COSMOS-Mind) began enrolling 2,262 people 65 or older without dementia to evaluate the effect of three years of ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

Against classical music and visual backdrops evoking Vienna, where the second AAT-AD/PD conference was to be held, the meeting instead unfolded Netflix-style. In this surreal age of COVID-19, the ...

The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...